Sysmex (OTCMKTS:SSMXY) Posts Earnings Results, Beats Estimates By $0.01 EPS

Sysmex (OTCMKTS:SSMXY) released its quarterly earnings results on Thursday. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01, reports. The company had revenue of $837.32 million for the quarter, compared to analyst estimates of $819.99 million. Sysmex had a return on equity of 9.32% and a net margin of 8.86%.

Sysmex Stock Down 9.6%

Shares of Sysmex stock traded down $0.90 during trading on Friday, hitting $8.52. The company’s stock had a trading volume of 132,855 shares, compared to its average volume of 217,265. Sysmex has a 52 week low of $8.15 and a 52 week high of $19.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34. The company has a fifty day simple moving average of $9.72 and a two-hundred day simple moving average of $11.33. The company has a market capitalization of $5.36 billion, a PE ratio of 17.75 and a beta of 1.14.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.